Amends GS 90-85.3A to allow a pharmacist to (1) administer drugs and (2) order and perform a CLIA-waived test to assist with clinical decision making relating to the use and monitoring of medications or treat influenza, COVID-19, pharyngitis caused by group A streptococcus and other health conditions screened by the test in accordance with statewide protocols. Prohibits a pharmacist from treating a health condition under GS 90-85.3A with any controlled Schedule 1-IV controlled substance. Defines CLIA-waived test as a lab test approved by the FDA and determined by the Centers for Medicare and Medicaid Services to qualify for a waiver under the federal Clinical Laboratory Improvement Amendments of 1988 and safe for use in non-laboratory settings. Effective October 1, 2025.

Enacts GS 58-3-241, requiring health benefit plans to cover healthcare services provided by pharmacists if (1) the service or procedure was performed within the pharmacist’s licensed scope of practice and (2) the health benefit plan would have covered the service if it had been performed by another healthcare provider. Defines healthcare provider, healthcare services, and pharmacist. Specifies that the participation of a pharmacy in a drug benefit provider network of a health benefit plan does not satisfy any requirement that insurers offering health benefit plans include pharmacists in medical benefit provider networks. Applies all requirements relating to coverage of prescription drugs and pharmacy services under GS Chapter 58 governing health benefit plans to third-party administrators as well as insurers. Amends GS 58-3-230 (uniform provider credentialing) to require insurers that delegate credentialing agreements or requirements for pharmacists licensed under Article 4A of GS Chapter 90 of the General Statutes or the relevant laws of another state to a contracted healthcare facility shall accept the credentialing for all pharmacists employed by, or contracted with, those healthcare facilities. Amends GS 58-3-200 (pertaining to miscellaneous insurance requirements) to require, upon notice or request from the insured, for the insurer to determine whether a healthcare provider able to meet the needs of the insured is available to the insured without unreasonable delay by reference to the insured's location and the specific medical needs of the insured. Effective October 1, 2025, and applies to insurance contracts entered into, renewed, or amended on or after that date.

Requires the State Health Director, in consultation with the NC Board of Pharmacy and Medical Board to develop statewide protocols relating to the modifications to GS 90-85.3A discussed above, including patient parameters necessitating referral to a primary, urgent, or emergency care provider.